Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic MIRACLE

This article was originally published in The Gray Sheet

Executive Summary

NYHA Class II heart failure patients appear to benefit from cardiac resynchronization therapy devices, according to results from Medtronic's MIRACLE ICD-II study, published in the Nov. 2 issue of Circulation. The 168-patient study showed that Class II patients treated with CRT-D devices exhibited a 58% improvement in a composite clinical endpoint at six months, compared with 36% for control patients, who received a CRT-D device with the CRT pacing function turned off. The company plans to combine the MIRACLE ICD-II study with data from other CRT studies, including the ongoing 500-patient REVERSE study, to expand the FDA-approved indication for CRT devices to include Class II patients. Class II represents about 2 mil. patients in the U.S. and 40% of all heart failure patients. Currently, CRT therapy is approved for Class III and IV patients (1"The Gray Sheet" June 2, 2003, p. 11)...

You may also be interested in...

Next-Generation CRT Trials Will Target Heart Failure Prevention

A bevy of clinical trials in development will reveal if cardiac resynchronization therapy (CRT) prevents the progression or even the initial onset of heart failure in at-risk patients

JAMA Editorial Praises MIRACLE ICD Study, Calls For More Substudies

An editorial by a Johns Hopkins physician in the May 28 Journal of the American Medical Association lends support to a growing number of electrophysiologists who have called on manufacturers to develop improved leads and guiding systems for cardiac resynchronization technology

QUOTED. 6 April 2020. Bethany Hills.

Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts